Clinical Trial Detail

NCT ID NCT03315026
Title Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

multiple myeloma

Therapies

Siltuximab

Age Groups: adult senior

No variant requirements are available.